Physician profile
Yan Wang
NPI 1699752444
$5,007.09
in general payments reported to CMS, 2019-2025
23 companies · $2,770 in 2025
The $2,770 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2022: $21.64 · 2023: $367 · 2024: $1,713 · 2025: $2,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,640 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,640.17 |
| Education | $209.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $684.83 | 2022-2025 | |
| Incyte Corporation | $580.71 | 2023-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $555.23 | 2023-2025 | Dupixent, Libtayo |
| Abbvie INC. | $449.55 | 2024-2025 | |
| Leo Pharma INC. | $409.47 | 2024-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $378.77 | 2023-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $362.35 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $304.69 | 2023-2025 | Sotyktu |
| Ucb, INC. | $202.95 | 2025 | Bimzelx |
| Galderma Laboratories, L.P. | $194.59 | 2023-2025 | Nemluvio |
| Amgen INC. | $152.51 | 2023-2025 | Otezla, Otezla |
| Pfizer INC. | $130.56 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $93.06 | 2024-2025 | |
| Lilly USA, LLC | $91.76 | 2024-2025 | Taltz, Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.35 | 2024 | Spevigo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $75.43 | 2023-2024 | Vtama |
| Celgene Corporation | $64.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.45 | 2019 | |
| Organon LLC | $48.13 | 2025 | Vtama |
| Convatec INC. | $35.27 | 2025 | |
| Journey Medical Corporation | $21.74 | 2025 | |
| Almirall LLC | $20.75 | 2024 | Klisyri |
| Dusa Pharmaceuticals, INC. | $20.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.